ABBV vs TGTX · P/E 81, rev $16.99B vs P/E 18, rev $240.3M
AbbVie Inc (ABBV) versus TG Therapeutics Inc (TGTX) — a side-by-side from cached financials, not a winner call.
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
TG Therapeutics Inc (TGTX) is a biotechnology company listed on NASDAQ.
Latest reported ABBV revenue for 2026-06-30 was $16.99B. Net income was $3.61B. Revenue was up 13.3% from 2026-03-31 to 2026-06-30. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
Latest reported TGTX revenue for 2026-06-30 was $240.3M. Net income was $7.8M. Revenue was up 17.3% from 2026-03-31 to 2026-06-30. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
Not investment advice. Open the ABBV and TGTX stock pages for the full models.
Not investment advice.